Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Solid Tumor × anlotinib × 1 year × Clear all

Sponsor

Conditions

Small Cell Lung Carcinoma 6 Carcinoma, Non-Small-Cell Lung 5 Thyroid Neoplasms 3 Sarcoma 3 Pancreatic Neoplasms 2 Gallbladder Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Cholangiocarcinoma 2 Breast Neoplasms 2 Whole-Brain Radiotherapy 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Proteinuria 1 Progression Free Survival(PFS) 1 Platinum-resistant Ovarian Cancer (PROC) 1 Lung Neoplasms 1 Limited Stage Small Cell Lung Cancer 1 Leiomyosarcoma 1 HER2-Negative Breast Cancer 1 Extensive Stage Lung Small Cell Cancer 1 Craniopharyngioma 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

pembrolizumab 6 Injections 5 tislelizumab 4 senaparib 4 Nivolumab 3 Bevacizumab 3 toripalimab 2 spartalizumab 2 Ipilimumab 2 Fluorodeoxyglucose F18 2 zimberelimab 1 tumor-cells apoptosis factor, human 1 tazemetostat 1 sotorasib 1 sintilimab 1 sacituzumab govitecan 1 rucaparib 1 romiplostim 1 osimertinib 1 olaparib 1 magrolimab 1 enzalutamide 1 cemiplimab 1 cedazuridine 1 binimetinib 1 atezolizumab 1 WW Domain-Containing Oxidoreductase 1 Ultrasonography, Doppler 1 Ultrasonography 1 Technetium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡